fda warning about compounded semaglutide July 29, 2024: issued new alert – Partnership for Safe Medicines Compounded "semaglutide" is not FDA-approved

Clinical trial starting doses The landmark phase 2 trial published in the New England Journal of Medicine randomized 338 participants across multiple dose groups

The patients who lose the most make healthy choices most of the time

Overall, weight loss associated with GLP-1 medications is often a result of the drug reducing the mental and physical cues that tell people to eat

Hypoglycemia risk : Lower risk than with insulin, but non-trivial if combined with other glucose-lowering medications

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage

Slower titration: Instead of increasing every 4 weeks, extending to 8 or even 12 weeks between dose increases gives the GI system more time to adapt